Alumis earnings release, August 13, 2026

Alumis Inc. (ALMS) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

​

Alumis Reports Second Quarter 2026 Financial Results and

Highlights Recent Achievements

​ – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – ​ – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – ​ – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 – ​

​

SOUTH SAN FRANCISCO, Calif., August 13, 2026 – Alumis Inc.

(Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended June 30, 2026, and highlighted recent achievements and upcoming milestones.

​

“Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases -- potentially unlocking broader potential of our TYK2 franchise,” said Martin Babler, President and Chief Executive Officer of Alumis. “The ONWARD3 long-term data delivered the highest reported PASI 100 response rate among oral therapies, positioning envudeucitinib to set a new standard in PsO. We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients.”

​

“Looking ahead, our main focus is on realizing our two TYK2 pipeline-in-a-pill franchise opportunities.” Babler added, “Based on the strength of clinical data to date, we are prioritizing Sjögren’s disease and cutaneous lupus erythematosus (CLE) as the next indications for envudeucitinib, subject to our LUMUS results and disciplined capital allocation. We are also advancing A-005, our CNS-penetrant TYK2 inhibitor, into a Phase 2 biomarker trial in Parkinson’s disease patients, planned to be initiated in the first half of 2027. Collectively, these programs underscore our goal to leverage the breadth of the TYK2 mechanism to pursue a broad range of immune-mediated diseases.”

​

Second Quarter 2026 and Recent Highlights

Envudeucitinib: a next

- generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate

- to

- severe plaque psoriasis

​

​

Envudeucitinib: Systemic Lupus Erythematosus (SLE)

​

TYK2 Franchise and Pipeline Update

​

Anticipated 2026 Milestones

​

​

​

​

Second Quarter 2026 Financial Results

​

Financial Guidance

​

About Alumis

Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, its central nervous system penetrant TYK2 inhibitor, with initial development focused on Parkinson’s disease and additional neuroinflammatory, neurodegenerative and peripheral immune-mediated disease indications under evaluation. For more information, visit www.alumis.com or follow us on LinkedIn or X.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:License revenue$—$—$—17,389
Revenue:Collaboration revenue1,6622,6663,4032,666
Revenue:Total revenue1,6622,6663,40320,055
Operating expenses:Research and development expenses85,337108,755166,877205,377
Operating expenses:General and administrative expenses23,35634,45041,96656,745
Operating expenses:Intangible assets impairment loss41,82441,824
Operating expenses:Total operating expenses150,517143,205250,667262,122
Operating expenses:Loss from operations-148,855-140,539-247,264-242,067
Other income (expense):Gain on bargain purchase187,907187,907
Other income (expense):Interest income4,9483,43010,2976,039
Other income (expense):Other income (expenses), net-71-38-64-82
Other income (expense):Total other income (expense), net4,877191,29910,233193,864
Other income (expense):Net income (loss) before income taxes-143,97850,760-237,031-48,203
Other income (expense):Income tax benefit1,7578,5611,7578,561
Other income (expense):Net income (loss)-142,22159,321-235,274-39,642
Other comprehensive income (loss):Unrealized gain (loss) on marketable securities, net-21630-871-18
Other comprehensive income (loss):Total comprehensive income (loss)-142,43759,351-236,145-39,660

Balance Sheet

December 31, — (Unaudited) (in thousands)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents63,70689,670
Current assets:Restricted cash82
Current assets:Marketable securities, current438,587218,831
Current assets:Research and development prepaid expenses4,3882,909
Current assets:Other prepaid expenses and current assets7,4036,740
Current assets:Total current assets514,084318,232
Current assets:Restricted cash, non-current1,3881,301
Current assets:Property and equipment, net16,84718,190
Current assets:Intangible assets9,13550,959
Current assets:Operating lease right-of-use assets, net17,27016,971
Current assets:Other assets, non-current1,8946,287
Current assets:Total assets560,618411,940
Current liabilities:Accounts payable12,80010,106
Current liabilities:Research and development accrued expenses35,57234,781
Current liabilities:Other accrued expenses and current liabilities16,37022,303
Current liabilities:Deferred revenue, current6,6691,458
Current liabilities:Operating lease liabilities, current4,8224,670
Current liabilities:Total current liabilities76,23373,318
Current liabilities:Operating lease liabilities, non-current31,60532,244
Current liabilities:Deferred tax liability3832,140
Current liabilities:Share repurchase liability71123
Current liabilities:Deferred revenue, non-current2,611
Current liabilities:Other liabilities, non-current168207
Current liabilities:Total liabilities108,460110,643
Stockholders’ equity:Common stock1210
Stockholders’ equity:Additional paid-in capital1,589,9791,202,975
Stockholders’ equity:Accumulated other comprehensive income (loss)-683188
Stockholders’ equity:Accumulated deficit-1,137,150-901,876
Stockholders’ equity:Total stockholders’ equity452,158301,297
Stockholders’ equity:Total liabilities and stockholders’ equity560,618411,940
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipates," "believes," "plans," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements, other than statements of historical facts, including without limitation those regarding the timing of the initiation of clinical trials, including a Phase 1 trial for the Company’s next clinical candidate, the timing and results of clinical data readouts in its ongoing clinical trials, including the Company’s Phase 2b LUMUS trial in systemic lupus erythematosus, as well as long-term and safety data in moderate-to-severe plaque psoriasis (PsO), the timing of the Company’s planned NDA submission with the FDA for envudeucitinib in PsO, the Company’s plans to prioritize Sjögren’s disease and cutaneous lupus erythematosus as additional indications for envudeucitinib, the Company’s goal to bring a new oral treatment option to patients with PsO and pursue a broad range of immune-mediated disease... (truncated)ety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking statements. Such risks and uncertainties include, without limitation, those related to Alumis’ ability to advance envudeucitinib or its other programs and to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing, costs, and results of preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, Alumis’ ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC) under the heading “Risk Factors” and elsewhere in such filings and reports, including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

​

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.